The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates
Open accessAbstract
The success of mRNA-based therapies depends on the availability of a safe and efficient delivery vehicle. Lipid nanoparticles have been identified as a viable option. However, there are concerns whether an acceptable tolerability profile for chronic dosing can be achieved. The efficiency and tolerability of lipid nanoparticles has been attributed to the amino lipid. Therefore, we developed a new series of amino lipids that address this concern. Clear structure-activity relationships were developed that resulted in a new amino lipid that affords efficient mRNA delivery in rodent and primate models with optimal pharmacokinetics. A 1-month toxicology evaluation in rat and non-human primate demonstrated no adverse events with the new lipid nanoparticle system. Mechanistic studies demonstrate that the improved efficiency can be attributed to increased endosomal escape. This effort has resulted in the first example of the ability to safely repeat dose mRNA-containing lipid nanoparticles in non-human primate at therapeutically relevant levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on these observations, Moderna has developed an ionizable lipid (namely Lipid H, SM-102), whose tail adopts larger branches which in turn increases potency, and whose introduced ester bonds increase biodegradability (Fig. 7).290,291”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [290]
In the citing paper
“All three major players in the mRNA vaccine field have previously optimized so-called lipid nanoparticles (LNPs), constructs that typically consist of an ionizable lipid and one or more helper lipids to improve LNP stability and promote endosomal escape upon cellular uptake [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [12]
In the citing paper
“the usage of the SM-102 lipid in Moderna's mRNA-1273 vaccine was found to outperform Onpattro's MC3 LNPs for the intramuscular (i.m.) delivery of mRNA in rodents and non-human primates, given its improved tolerability and higher endosomal escape efficiency [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [12]
In the citing paper
“Endosomal escape can be increased by optimizing the pKa values of ionizable lipids66,76–78,88,100,140.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [77]
In the citing paper
“To improve the biocompatibility of lipid nanoparticles, biodegradable lipids can be applied76–78,108,179.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [77]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [77]
Citations
Cites
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Tools for translation: non-viral materials for therapeutic mRNA delivery
Hajj, K. A., & Whitehead, K. A. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.56 · Cited by 799
Bahl, K., Senn, J. J., Yuzhakov, O., Bulychev, A., Brito, L. A., Hassett, K. J., Laska, M. E., Smith, M., Almarsson, Ö., Thompson, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.035 · Cited by 642
Self-citationMaier, M. A., Jayaraman, M., Matsuda, S., Liu, J., Barros, S., Querbes, W., Tam, Y. K., Ansell, S. M., Kumar, V., Qin, J., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.124 · Cited by 625
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 820
Monodisperse mRNA-Loaded Lipid Nanoparticles Enabled by Optimizing an Ionizable Cationic Lipid
Toyoda, Y., Miyazaki, Y., Tsuda, S., Yamamura, H., Shimada, N., & Akiba, I. (2026) · Langmuir · doi:10.1021/acs.langmuir.5c05504 · Cited by 1
Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues
Douros, J. D., Capozzi, M. E., Novikoff, A., Mokrosiński, J., DUBOIS, B. N., Stock, J., Rohlfs, R., Anderson, M., Jedrzejcyk, D. J., Poulsen, S., et al. (2026) · Molecular Metabolism · doi:10.1016/j.molmet.2026.102327 · Cited by 1
“The ionizable lipid (heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate) was synthesized as previously described [17].”
Doering, J., Adewunmi, Y., Deal, C. E., Plante, O. J., Carfı́, A., & Mantis, N. J. (2026) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0013518 · Cited by 1
“Lipid nanoparticle-formulated mRNA was produced through a modified ethanol-drop nanopre-cipitation process as described [17].”
Drinkable gene therapy foam for the treatment of constrictive esophageal carcinoma
Stephan, S. B., Cummings, C. L., Fitzgerald, K., & Stephan, M. T. (2026) · Gene Therapy · doi:10.1038/s41434-026-00592-7 · Cited by 1
Ionizable lipids as a promising platform for creating mRNA vaccines
Milagina, S. V., & Puchkov, P. A. (2026) · Fine Chemical Technologies · doi:10.32362/2410-6593-2026-21-1-51-72 · Cited by 1
Che, J., Guo, Y., Guo, L., Liu, J., Li, T., & Fei, Y. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s577606 · Cited by 1
“30,31 The co-encapsulation of two distinct mRNA species within a single LNP formulation ensures synchronized expression of both BsAbs, which is critical for achieving synergistic T-cell activation.”
Wang, B., Hao, Y., Hong, W., Bai, Z., Qin, F., Ai, J., Liu, J., Alu, A., Gao, Z., Wu, Y., et al. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103039 · Cited by 1
Kumar, M., Tiwari, S., Rajwade, A., Kulkarni, R., Patel, A., & Shah, D. K. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04086-4 · Cited by 1
“Despite the significant surge in research interest in recent years, most studies involving mRNA-LNP have focused on optimizing the formulations [3, 4] or assessing pharmacodynamic (PD) endpoints in preclinical species [5].”
mRNA vaccines for viral diseases: mechanism, advances, and future perspective
Chakraborty, B., & Singh, T. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11856-1 · Cited by 1
Dyett, B., Alsaiari, S. K., Daristotle, J. L., Forster, T. A., Lau, A., Varshney, D., Afaneh, R., Hanna, A. R., Sloane, C., Mankus, D. V., et al. (2026) · Advanced Functional Materials · doi:10.1002/adfm.75716 · Cited by 1
“LNPs were prepared according to previously described methods [22, 74].”
Li, L., Wang, M., Ye, X., Liu, Z., Duan, Y., Chen, X., Ouyang, Y., Wu, Q., Sun, M., & Xie, T. (2026) · MedComm · doi:10.1002/mco2.70700 · Cited by 1
Nano‐Enabled Toxicity of Pharmaceutical Excipients
Polidori, I., Werner, L., & Bernkop‐Schnürch, A. (2026) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70062 · Cited by 1
Kumarasinghe, E. S., Hennessy, E. J., Danneman, M. W., Burke, K. E., Salerno, T., Giardino, E. E., Crawford, M. D., Thomas, E. L., Markaj, P. L., Mahmoudinobar, F., et al. (2026) · Small Science · doi:10.1002/smsc.70314 · Cited by 1
“Most prior research has focused on understanding structure – activity relationships (SARs) among these elements, yet predictive models linking ionizable lipid properties to biological performance remain elusive [13, 21 – 24].”
Self-citationFrom LNPs to hybrid nanocarriers: development, challenges and redesign of non-viral gene delivery
Wu, W., Wei, Z., & Peng, X. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04622-9 · Cited by 2
“Collectively, these features endow L319 with superior pharmacokinetic and safety profiles, making it a promising platform lipid for vaccines, protein replacement therapies, and other mRNA-based interventions [10].”
Ciganek, I., Delehedde, C., Galy, A. H. M., Cogné, M., Rameix, N., Bordeianu, C., & Pichon, C. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103334 · Cited by 2
“…acid phosphates (N/P ratio), lipid tail branching, pKa tuning, and inclusion of biodegradable bonds (e.g. esters or disulfides) in ionizable lipids significantly impact LNP stability, cargo loading, in vivo distribution and protein corona formation, along with intracellular processing [136 – 139].”
Wu, W., Wei, W., Ge, H., Yang, D., Han, T. T., Yao, Y., Qian, Y., Wang, Y., Tao, S., She, L., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115117 · Cited by 1
Zhu, X., Sun, H., Cao, X., & Xia, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105448 · Cited by 1
Membrane environment sets the functional pKa of ionizable lipids
Trollmann, M. F. W., Rossetti, P., & Böckmann, R. A. (2026) · Biophysical Journal · doi:10.1016/j.bpj.2026.06.030 · Cited by 4
“Processes such as PEG shedding, 68 anti-PEG immune responses, 69 aminolipid metabolism, 70,71 endosomal maturation, 72 protein binding, 66 inflammation exacerbation, 73 and organ tropism 74 remain beyond the scope of current atomistic simulations.”
Tiwari, S., Kumar, M., Wu, S., Kulkarni, R., & Shah, D. K. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01273-4 · Cited by 2
“For example, IV administration of mRNA-LNP in non-human primates yielded the highest mRNA levels in spleen (21) .”
Wiedermann, U., Wagner, A., Bartuschka, A., Berghoff, A. S., Donschacher, A., Eser, A., Förster‐Waldl, E., Göschl, L., Grabmeier‐Pfistershammer, K., Keil, F., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02754-4 · Cited by 2
Yuen, B. P., Wong, K., Cheung, H. W., Ho, E. N. M., & Wong, W. (2026) · Journal of Chromatography A · doi:10.1016/j.chroma.2026.467244 · Cited by 1
Zeng, Y., Xu, J., Wang, J., Xue, L., Liu, J., Geisler, H. C., Xu, M., Melamed, J. R., Shi, Q., Padilla, M. S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2525718123 · Cited by 1
Optimized Lipid Nanoparticles with Tail‐Modified Ionizable Lipids for Safer mRNA Delivery
Bae, S., Lee, J., Ahn, J.-H., Choi, H., Choi, H., Kim, J., Kang, M., Oh, H. R., Park, S. H., Oh, E. Y., et al. (2026) · Advanced Science · doi:10.1002/advs.76539 · Cited by 1
“…demonstrating that optimal mRNA delivery is often achieved through a balanced hydrophobic tail architecture rather than maximal hydrophobicity alone, suggesting that similar design principles may apply across multiple ionizable lipid scaffolds despite differences in head-group chemistry [ 3, 33 ].”
Takano, T., Matsumura, T., & Takahashi, Y. (2026) · International Immunology · doi:10.1093/intimm/dxag040 · Cited by 1
Non-invasive nanoparticle barcoding in nonhuman primates
Jang, B., Zenhausern, R., Lian, L., Gentry, K., Abbas, A. M., Rudden, S., Shin, Y.-J., Doan, J., Loughrey, D., Curran, E. H., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03262-6 · Cited by 1
Jiang, K., Shao, B., Li, R., Liang, T., You, C., Wang, L., Cen, J., Tan, J., Zhang, Y., Chen, M., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.3823572 · Cited by 1
Advances in mRNA Delivery and Clinical Applications
Hu, B., Hussain, A., Liu, Q. L., Weng, Y., & Huang, Y. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_13 · Cited by 1
Emerging Concepts in Leishmania Vaccine Adjuvants
Das, A., & Ali, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-6999-9_17 · Cited by 1
Comparative Function Analysis of Self‐Amplifying mRNA and Self‐Amplifying DNA
Li, W., Wang, Y., Wang, C., Huo, Y., & Lu, Y. (2025) · ChemBioChem · doi:10.1002/cbic.202500110 · Cited by 1
Application of quantitative and engineering biology in mRNA gene therapy
Xiang, H., Ke, L., Yang, X., Guo, J., Yang, W., & Hu, Y. (2020) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2020-0476 · Cited by 1
Gene Therapy for Inherited Metabolic Diseases
Longo, N., & Lai, K. (2022) · Springer eBooks · doi:10.1007/978-3-030-94510-7_8 · Cited by 1
IL-1β and IL-1ra are key regulators of the inflammatory response to RNA vaccinesPreprint
Mellman, I., Tähtinen, S., Tong, A.-J., Himmels, P., Oh, J., Paler-Martı́nez, A., Kim, L., Wichner, S. M., Oei, Y. A., McCarron, M. J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-378991/v1 · Cited by 1
Gene Delivery Using Nanocarriers
Vhora, I., & Khatri, N. (2021) · Wiley eBooks · doi:10.1002/9781119769897.ch9 · Cited by 1
Lipid nanoparticles for delivery of gene editing components
Kang, D. D., & Dong, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822425-0.00096-8 · Cited by 1
pH-Sensitive Amino Lipid-Driven Pore Formation Enables Endosomal Escape of Lipid NanoparticlesPreprint
Singh, A. P., Shibata, K., Miyazaki, Y., & Shinoda, W. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.15.688617 · Cited by 1
Peptide nanoparticles for systemic mRNA delivery in rodents and non-human primatesPreprint
Lehto, T., Sork, H., Lorents, A., Rädler, J., Bazaz, S., Roudi, S., Gustafsson, O., Boukary, O., Talgre, I. R., Hällbrink, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.26.690657 · Cited by 1
“Based on literature, for hPep3 PNPs at 1 mg/kg the peak serum hEPO concentrations were comparable to those achieved with MC3 LNPs at 0.01 mg/kg [38,39] and C12-200 LNPs at 0.05 mg/kg [42] and 2-fold lower than Lipid 1 LNPs at 0.1 mg/kg [40], making them roughly 100-fold, 20-fold and 20-fold more…”
InfluentialDesigned synthesis of silica based nanocarriers for mRNA delivery
Wang, Y. (2020) · The University of Queensland · doi:10.14264/b28d1e7
"Venceréis pero no convencéreis": encontronazo en Salamanca
Florencio, R. N. (2014) · La Aventura de la historia
Schwab, S. R. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737211442.793571253
Delivery and Formulation Methods for Therapeutic Genome Editing
Blenke, E. O., & Krishnamurthy, V. R. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch18
Answering to social issues – Delivery of mRNA vaccines and therapeutics
Uchida, S. (2022) · Drug Delivery System · doi:10.2745/dds.37.25
Rapid vaccine development, only with the developed DDS technology
Takeda, M. (2021) · Drug Delivery System · doi:10.2745/dds.36.4
RNA/Polymer-Based Supramolecular Approaches for mRNA Delivery
Boonstra, E., Uchida, S., & Cabral, H. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_15
Jackson, N. A. C. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_2
Exogenous RNAs as Potential Pharmacological Agents
Okovitiy, S. V., & Шустов, Е. Б. (2022) · Journal Biomed · doi:10.33647/2074-5982-18-3-118-121
Chandler, M. R., Danai, L., & Afonin, K. A. (2022) · Springer eBooks · doi:10.1007/978-981-16-1313-5_99-1
Zhao, S.-Q., Chi, H., Qin, C., & Deng, Y. (2023) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2022-1097
Data from Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment
Hewitt, S. L., Bailey, D., Zielinski, J., Apte, A., Musenge, F. M., Karp, R., Burke, S., Garçon, F., Mishra, A., Gurumurthy, S., et al. (2023) · doi:10.1158/1078-0432.c.6529685
Cirella, A., Bolaños, E., Trani, C. A. D., de Andrea, C. E., Sánchez‐Gregorio, S., Etxeberría, I., González-Gomariz, J., Olivera, I., Brocco, D., Glez‐Vaz, J., et al. (2023) · doi:10.1158/2326-6066.c.6551084
Cirella, A., Bolaños, E., Trani, C. A. D., de Andrea, C. E., Sánchez‐Gregorio, S., Etxeberría, I., González-Gomariz, J., Olivera, I., Brocco, D., Glez‐Vaz, J., et al. (2023) · doi:10.1158/2326-6066.c.6551084.v1
Chandler, M. R., Danai, L., & Afonin, K. A. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_99
Azagury, A., Kaeek, M., Khoury, L. R., & Kost, J. (2023) · Wiley eBooks · doi:10.1002/0471238961.0418210717210104.a01.pub3
Walther, J., Porenta, D., Wilbie, D., Seinen, C. W., Benne, N., Yang, Q., de Jong, O. G., Lei, Z., & Mastrobattista, E. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4580331
Lipid Nanoparticle-Mediated Delivery of CRISPR-Cas9 for Therapeutic Gene Correction
Walther, J. (2023) · Utrecht University Repository (Utrecht University) · doi:10.33540/2032
La technologie de l’ARN messager
Laroui, N., & Pichon, C. (2023) · Actualités Pharmaceutiques · doi:10.1016/s0515-3700(23)00474-3
Revealing the Dynamic Process of Mrna Delivery by Lipid Nanoparticles in VivoPreprint
Ma, R., Li, Y., Wei, Y., Zhou, J., Ma, J., Zhang, M., Tu, J., Jiang, J., Xie, S., Tan, W., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4797877
Liposomes as DNA, mRNA and oligonucleotide delivery vectors
Nele, V., Campani, V., & Rosa, G. D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15491-1.00012-2
Yoon, I., Xue, L., Chen, Q., Liu, J., Xu, J., Siddiqui, Z., Kim, D., Chen, B., Shi, Q., Han, E. L., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202415389
Jung, H. Y., Kim, T. H., Hadinoto, K., & Park, J.-W. (2024) · Tenside Surfactants Detergents · doi:10.1515/tsd-2024-2610
Immune Responses to mRNA Vaccine
Exposito, J., Monge, C., Arruda, D. C., & Verrier, B. (2024) · Wiley eBooks · doi:10.1002/9783527838394.ch2
Nanomedicine’s Role in the COVID-19 Vaccine Development and Optimization
Kumar, J., Malhotra, J., Yadav, A. S., & Bhati, A. S. (2024) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-72467-1_3
Nanotechnology for cancer immunotherapy
Zheng, X., Manshian, B. B., & Soenen, S. J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00039-4
Maternal transfer of mRNA LNP-derived, pathogen-specific, monoclonal IgG to suckling micePreprint
Doering, J. E., Adewunmi, Y., Deal, C. E., Plante, O. J., Carfı́, A., & Mantis, N. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.12.642889
Development and application of fluorescence RNA imaging tools
Yin, P., Wang, J., Huang, C., KUANG, S., & Nie, Z. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0300
“…小体和 U 小体进行 SIM 成像，观察到应激颗粒中 RNA 的不均匀分 布，有助于研究应激颗粒的结构和功能 [65] 。其课题组开发的绿色荧光 RNA 适配 体 Okra ，具有高亮度和光稳定性，长时间连续光照下能保持 90% 荧光，适用于 活细胞中 RNA 的双色超分辨率成像 [66] 。 粒子递送后的 RNA 逃逸，并区分细胞质与核内封闭的 RNA [118] ； RIBOmap 技术 用于表征细胞和组织样本中化学和拓扑修饰的 RNA 治疗和翻译活性 [119] ； Satija 课题组结合外界干扰模型与单细胞 RNA 测序，探究了聚腺苷化调节因子的作用 机制 [120] A d”
Novel approaches to immuno-oncology
Chen, R., & Su, F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-14064-8.00047-3
Investigation of in vitro delivery conditions for self-amplifying mRNA
Li, W., Wang, Y., Huo, Y., & Lu, Y. (2025) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-025-03215-4
“Approximately 18 h later, the solution in the dialysis bag was aseptically filtered using a 0.22 μm filter to obtain the LNP-SAM mixture [32].”
InfluentialSon, J., Yoo, H., Park, J., Park, H., Chong, S., Lee, J., Kim, J., Park, E., Bae, S.-H., Kang, S.-H., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102697
“32,59 Bridging studies in non-human primates will be necessary to assess biodistribution, long-term expression, and long-term toxicity.”
InfluentialLuongo, C. A., Wright, A. D., Lochmann, T. L., Rihani, S. B. A., Marshall, J.-C. A., Jani, D., Pennucci, J. J., & Ortiz, J. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01126-6
“The mRNA-LNP drug product was prepared as previously described (10–12).”
Bedside manufacturing of engineered stem cells using gene therapy foam
Cummings, C. L., Stephan, S. B., Fitzgerald, K., & Stephan, M. T. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101612
“15 We, therefore, do not expect any of the material components we are injecting to induce toxicities.”
Chen, C. H., Dane, E. L., Oag, S., Sand, E., Andersson, P. U., Bak, A., & Zhou, L. (2025) · Organic & Biomolecular Chemistry · doi:10.1039/d5ob01888a
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection
Chavalparit, T., Barry, C. P., Gunter, H., Gillard, M., Mercer, T. R., & Marcellin, E. (2025) · mAbs · doi:10.1080/19420862.2025.2599584 · Cited by 1
“27 In contrast, pDNA-based expression may require up to 14 days to reach Protein production from the original DNA or stable transfection initiates from DNA transcription into mRNA inside the nucleus.”
Therapeutic potential of exogenous mRNA encoding recombinant antibodies against viral pathogens
Klotchenko, S. A., & Plotnikova, M. A. (2025) · Medical academic journal · doi:10.17816/maj642736
mRNA-based vaccines: Rational antigen design, delivery optimization, and immune modulation
Liu, S., Shi, H., Dai, D., Tian, T., Duan, X., Sun, J., Xu, W., Yin, X., Xie, Y., & Song, X. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112312
Ferrocene-contained cationic lipids via Ugi reaction for gene delivery and tumor cell ferroptosis
Wang, R., Tian, X., Li, J., Chen, J., Hu, Y., & Zhang, J. (2026) · Journal of Materials Science · doi:10.1007/s10853-026-12175-3
“However, most clinically used LNPs (e.g., DLin-MC3-DMA, SM-102, and ALC-0315) were synthesized through complex chemical reactions [38, 39].”
Niwa, T., Onishi, Y., Tamura, M., Kasuya, Y., Nishiya, T., Sugiyama, D., Yoshida, T., Tozuka, M., Namba, E., Miyaji, K., et al. (2026) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2026.2615355
“We also compared the inhibitory activities of the LNPs using LIPIDs-1 with those using MC3 (DLin-MC3-DMA), [8] which is the gold-standard lipid for LNPs.”
InfluentialHow has the inclusion of unconventional lipids improved LNP-mediated mRNA delivery?
Zhou, M., Chen, J., Zheng, Z., Du, S., & Hou, X. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2621726 · Cited by 1
Nandalal, S., Haridoss, M., & Lenin, R. R. (2026) · Journal of Liposome Research · doi:10.1080/08982104.2026.2618747
“Cholesterol is effective in filling gaps caused by imperfect lipid arrangement, elasticity, and permeability [33–36], which is vital for stability during storage and while transport through ocular barriers [37,38].”
Ruano, M., Ozichi, C., Bedford, M. R., Mullen, A. B., Kelemen, D. W., & Ferro, V. A. (2026) · Exploration of BioMat-X · doi:10.37349/ebmx.2026.101362
Linares-Fernández, S. (2021) · theses.fr (ABES) · doi:10.70675/17ec09cezeb11z45f7z8529z7ffbf89d664a
Vectorisation d'ARN par voie orale et parentérale
Stalder, T. (2024) · theses.fr (ABES) · doi:10.70675/d509592fzbb96z4f17zb286z5040de22fd65
Peña, Á., Broset, E., Lucía, E. G., García-Latorre, L., Navarro, V., Matute, C., Gallego-Lleyda, A., Alejo, T., Romanos, E., García, A., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040472
Engineering mRNA therapeutics for protein supplementation: Challenges and future horizons
Tao, Y., Zhao, Y., Su, Q., Pan, J., Yin, J., & Xu, C. (2024) · BME Horizon · doi:10.70401/bmeh.2026.0025
Metabolism of the ionizable lipid SM-102 in liver microsomes, 2D hepatocytes, and 3D liver spheroids
Sun, B., Jin, Z., Li, X., Xiao, X., Jiang, Z., Xie, W., Zhang, L. W., & Deng, P. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100323
The Role of DMSO in RNA Therapeutics and Lipid Nanoparticle Formulations
Hickey, M. B., & Almarsson, Ö. (2026) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-032-19256-1_11
Self-citationPredicting polymer drug delivery efficiency using 3D molecular structures and deep learningPreprint
Lee, S. A., Ahn, J., Shin, S., Kim, B. S., Shin, Y., Kim, D., Tiruchinapally, G., Maity, S., Roeise, J., Necoechea, C. A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9445168/v1
Ongun, M., Kola, N. S., Patel, D., Rodrigues, T. C., Schmidt, S., Lokras, A. G., Franzyk, H., Paludan, S. R., Rades, T., Thakur, A., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-60179-5
Bian, H., Tse, W. W., Huang, G., & Liu, S. (2026) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbag019
“Incorporating pH-responsive ionizable lipids resolves this by facilitating endosomal escape, preventing the diversion of entrapped mRNA to lysosomal degradation pathways [ 160 , 161 ].”
Injectable bioinstructive microfoam for rapid bedside/in vivo programming of CAR-T cells
Stephan, S. B., Cummings, C. L., Fitzgerald, K., West‐Foyle, H., Cavanaugh, E. J., Zeytin, İ. C., Radtke, S., Kiem, H., Heczey, A. A., & Stephan, M. T. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.07.037
Optimization of Therapeutic modRNA Delivery to the Lung for Prevention of Pulmonary Fibrosis
Mainkar, G., Żak, M. M., Ghiringhelli, M., Yoo, J., Adjmi, M., Kaur, K., & Zangi, L. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070868
“The panel included a formulation utilizing Lipid 5, chosen as a control due to its known high multi-tissue transfection efficiency and neutral charge [25].”
Lee, S., Kim, S., Kim, S., Kyung, K., Kim, G., 남정표, Lee, J., Jeong, S., Seo, G., & Cho, H. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115176
Spleen-targeted drug delivery: A promising yet ignored arena
Sabale, P. D., & Dhaneshwar, S. S. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108730
Nanotechnology-Enabled Therapeutic Cancer Vaccines: From Antigen Design to Delivery
Su, B., Cao, J., Wang, Z., Gao, H., Ren, D., Huang, W., Wang, L., & You, Y. J. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00109
Singh, A. P., Łazarski, G., Miyazaki, Y., Nagano, S., & Shinoda, W. (2026) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.6c00869
Sriram, V., Phatangare, V., & Lee, J. (2026) · Biomaterials Science · doi:10.1039/d6bm00568c
Jugniot, N. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119213
Cascading attrition of in vivo CAR-T therapy: From systemic delivery failure to functional collapse
Rao, H., Xu, S., Chen, J., & Guo, Z. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105521
Redox-responsive nanomaterials for mRNA delivery: From rational design to therapeutic applications
Li, M., Wang, Y., Gao, J., An, S., Tang, Z., & Tao, W. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115942
Chen, J. J., Lawanprasert, A., Kleinhenz, A. L. W., Namala, M. G. D., Chu, D., Tang, Y., Lindarto, V., Launspach, M., Lee, D., Wu, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.04.741347
Macromolecular Design Principles for Polymer‐Lipid Hybrid Nanoparticles in RNA Delivery
Shao, B., Chen, M., & Liu, S. (2026) · Macromolecular Rapid Communications · doi:10.1002/marc.70402 · Cited by 1
“Subsequent optimization of amino lipid structures and intramuscular mRNA vaccine formulations further established ionizable lipid LNPs as a major platform for RNA therapeutics (Figure 1 ) [ 18, 19 ].”
Metadata
- Authors
- Sabnis, S., Kumarasinghe, E. S., Salerno, T., Mihai, C., Ketova, T., Senn, J. J., Lynn, A., Bulychev, A., McFadyen, I., Chan, J., Almarsson, Ö., Stanton, M. G., & Benenato, K. E.
- Affiliations
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Benenato, Kerry E.
- ORCID
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 26
- Issue
- 6
- Pages
- 1509-1519
- ISSN
- 1525-0016 (ISSN-L)
- PMC
- PMC5986714
- OpenAlex
- W2791854174
- Cited by
- 820
- References
- 20
- Citations by year
- 2026: 107 · 2025: 139 · 2024: 156 · 2023: 139 · 2022: 116 · 2021: 73 · 2020: 51 · 2019: 31 · 2018: 7
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- mRNA delivery, lipid nanoparticles, endosomal escape, structure-activity relationship, pharmacokinetics, toxicology, non-human primates
- MeSH terms
- Animals, Lipids, Primates, RNA, Messenger, Rats, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
